OXiGENE Inc (NASDAQ:OXGN), a biopharmaceutical company developing novel cancer therapeutics, announced that it has entered into definitive agreements with institutional investors to purchase an aggregate of $16 million of registered shares of OXiGENE common stock in an at-the-market direct offering at $ 2.9625 per share. OXiGENE Inc (NASDAQ:OXGN), weekly performance is -11.73%. On last trading day company shares ended up $2.71. Analysts mean target price for the company is $7.50. OXiGENE Inc (NASDAQ:OXGN), distance from 50-day simple moving average (SMA50) is -17.68%.
On May 14, 2014, Sorrento Therapeutics Inc (NASDAQ:SRNE), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, announced the pricing of an underwritten public offering of 4,765,000 shares of common stock at a public offering price of $5.25 per share. Sorrento Therapeutics Inc (NASDAQ:SRNE), fell 5.57% in last trading session and ended the day on $4.92. SRNE, return on assets is -65.10%. Sorrento Therapeutics Inc (NASDAQ:SRNE), quarterly performance is -49.64%.
Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced detailed results from its previously completed Phase IIa trial investigating ORMD-0801, its orally ingestible insulin capsule, in type 2 diabetes patients. Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP), shares moved down 17.80% in last trading session and was closed at $17.71, while trading in range of $7.51 – 9.44. Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP), year to date (YTD) performance is -50.03%.
On May 16, 2014, Vermillion, Inc. (NASDAQ:VRML), posted a loss of $4.2 million in the first quarter, or 11 cents per share, on revenue of $305,000, compared to a loss of $2.6 million, or 17 cents per share, on revenue of $328,000 in the year-earlier period. Vermillion, Inc. (NASDAQ:VRML), ended the last trading day at $2.59. Company weekly volatility is calculated as 7.23% and price to cash ratio as 3.15. Vermillion, Inc. (NASDAQ:VRML), showed a negative weekly performance of 12.50%.